Home/Pipeline/Influenza Vaccine

Influenza Vaccine

Influenza

PreclinicalActive

Key Facts

Indication

Influenza

Phase

Preclinical

Status

Active

Company

Medigen

About Medigen

Medigen is a preclinical-stage biotech company developing a pipeline of vaccines for significant unmet medical needs, including Chikungunya, Venezuelan Equine Encephalitis (VEE), Lassa fever, and influenza. Its strategy is built on a proprietary vaccine technology platform designed to elicit safe and robust immune responses. The company is expanding its physical footprint for manufacturing and R&D, indicating a transition towards clinical development and potential contract manufacturing capabilities. As a private entity with no marketed products, it remains in a pre-revenue, R&D-intensive phase.

View full company profile

Therapeutic Areas

Infectious Disease Oncology

Other Influenza Drugs

Drug	Company	Phase	Status
PanCytoVir™ (oral probenecid)	TrippBio	IND Submitted	Active
Mimotopes-004	Mimotopes	Preclinical	Active
Next-Gen / Universal Flu Vaccines	CSL Seqirus	Research / Early Clinical	Active
Oseltamivir 75 mg	MSN Laboratories	Commercial	Active
AI Programme - Influenza	Poolbeg Pharma	Discovery	Active - Target/Candidate ID
Influenza Antibodies	new/era/mabs	Research/Pre-clinical	Active
Influenza Countermeasure Program	DynPort Vaccines	Not Specified	Active
Nasal Influenza Vaccine	Abera Bioscience	Pre-clinical	Active
Zapnometinib (ATR-002)	Atriva Therapeutics	Phase 2	Active
EV25	Eradivir	Pre-clinical	Active
Not Specified	New Amsterdam Sciences	Pre-clinical	Active
Influenza Program	Arisan Therapeutics	Preclinical	Active